Disclosures for "Community-based Brain Health Screening Through Portable MRI and Brain-age Modeling"
-
Ms. Brigger has nothing to disclose.
-
Mr. Johnson has nothing to disclose.
-
Ms. Shanks has nothing to disclose.
-
Ms. Maynez has nothing to disclose.
-
Mrs. Champagne has nothing to disclose.
-
Dr. Rivier has nothing to disclose.
-
Mrs. Johnson has nothing to disclose.
-
Mr. De Both has nothing to disclose.
-
Ms. Metz has nothing to disclose.
-
Mr. Chambers has nothing to disclose.
-
Ms. Price has received personal compensation for serving as an employee of TGen.
-
Miss Barraza has nothing to disclose.
-
Ms. Moore has nothing to disclose.
-
Mr. Piras has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer.
-
Dr. Agrawal has nothing to disclose.
-
Jua Iglesias Gonzalez has nothing to disclose.
-
Annabel Sorby-Adams has nothing to disclose.
-
Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrocyte Pharmaceuticals. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Kimberly has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Stryker. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics. Dr. Kimberly has stock in Woolsey Pharmaceuticals. Dr. Kimberly has stock in Acasti Pharma. The institution of Dr. Kimberly has received research support from NIH. The institution of Dr. Kimberly has received research support from Hyperfine, Inc.. The institution of Dr. Kimberly has received research support from Alzheimer's Association. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
-
Matthew Huentelman has nothing to disclose.
-
Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.